

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has entered into an exclusive license agreement (the “**Agreement**”) with AstraZeneca for the global development, manufacture and commercialisation of the Group’s Lipoprotein(a) (Lp(a)) inhibitor, YS2302018 (the “**Compound**”) and any pharmaceutical or biological product subsequently developed that is comprised of or contains the Compound (the “**Products**”).

Under the terms of the Agreement, the Group agreed to grant an exclusive license to AstraZeneca to develop, manufacture and commercialise the Compound and the Products worldwide. The Group will receive an upfront payment of US\$100 million, and is also eligible to receive up to US\$370 million in potential development milestone payments and up to US\$1,550 million in potential sales milestone payments, plus tiered royalties based on annual net sales of the Products.

ABOUT THE COMPOUND

As a leading pre-clinical drug candidate, the Compound was discovered by the Group’s AI-driven small molecule drug design platform. This platform used AI technology to analyse the binding patterns of target proteins with existing compound molecules, conducted targeted optimisation of their drug-like properties, and ultimately selected a highly effective small molecule inhibitor of Lp(a) with excellent developability. The Compound has been shown to effectively bind to Apolipoprotein(a) (Apo(a)), thereby preventing its assembly with ApoB-100 particles to form Lp(a). Pre-clinical data have demonstrated that the Compound has a superior pharmacokinetic (PK) profile and enhanced efficacy in both in vitro and animal models, without significant safety risks, and hence has the potential to become a novel therapy for controlling cardiovascular risk in populations with high Lp(a).

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 7 October 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.